If you're coming to Mason Schroeder's memorial service, be sure to wear
your brightest clothes.FIG1
Mason Schroeder died at the age of 11 of adrenoleuko-dystrophy. His case
formed the backstory to a resolution on newborn genetic screening that was
brought by the Section Council on Psychiatry to the AMA House of
Photo courtesy of Mary Kelling
That was the word that went out to acquaintances of the vibrant 11-year-old
Sheboygan Falls, Wis., boy who died last year of what was determined only six
months before his death to be adrenoleukodystrophy. Featured in the 1992
movie, "Lorenzo's Oil," the disorder is an X-linked genetic
condition that progressively destroys myelin tissue insulating nerves of the
central and peripheral nervous system. The condition causes any number of
behavioral symptoms that mimic, and can be masked by, other psychiatric and
At the memorial service in Settlers Park in Sheboygan Falls, where members
of the community came in their brightest colors to commemorate the boy's life,
was Mason's child psychiatrist, Jenna Saul, M.D. She first began treating
Mason in July 2006 for what was presumed to be
attention-deficity/hyperactivity disorder (ADHD).
"I struggled with what I could have done differently or sooner, why I
wasn't more aggressive about thinking about other diagnoses," she said."
In retrospect I don't think I would have ever thought about doing
something different or more."
Though the disease can be detected by a blood test, there is no cure.
Expensive bone-marrow transplants can sometimes slow or halt the progression
of the disease, as can "Lorenzo's oil"—a 4:1 mixture of
glycerol trioleate and glycerol trierucate—along with dietary changes.
It is questionable how much difference an earlier diagnosis might have made to
While there was no neonatal genetic test for the condition at the time of
the boy's birth, there is one being pilot tested by researchers at the Kennedy
Krieger Institute in Baltimore. Saul believes that early detection can spare
other parents the distress of living in the dark about their child's illness
and increase the chances of extending survival with early and aggressive
Mason's illness is the story of a psychiatrist treating a child with a
condition that inhabits a border where psychiatry, neurology, and genetics
meet. And it is also the story of how a searing clinical encounter with a
baffling illness was the impetus for bringing the cause of universal neonatal
genetic screening to the policymaking body of the AMA.
At the memorial service that day last year, the boy's mother, Mary Kelling,
sought out the child psychiatrist who had come with the others to say goodbye
to Mason. "I told her not for one second would I blame her" for
not coming upon the right diagnosis earlier, Kelling told Psychiatric
"I was astounded," Saul said. "Here she was at her son's
memorial service and she was seeking me out to look after me."
Saul first began to see Mason as a patient in July 2006 when he was 9.
Previously, he had been treated by a pediatrician for ADHD.
Mason Schroeder was diagnosed correctly with adrenoleukodystrophy only
months before he died at age 11. He was initially treated for ADHD, but the
psychiatrist who took over his care investigated her suspicions of a more
serious neurological disorder.
Photo courtesy of Mary Kelling
"When he first came to see me, there were some quirky aspects to his
behavior that made me wonder about a pervasive developmental disorder,"
Saul recalled. "But his history didn't support it because he'd had
fairly normal early
His progress in treatment came in fits and starts. "At one point he
was hospitalized, and I remember thinking that the picture just wasn't adding
up," Saul said. "I was seeing a lot of behaviors that seemed like
autism, but the developmental history wasn't consistent."
She sought to have a pediatric neurologist read an ambulatory EEG on Mason."
I wanted to be looking for abnormal electrical currents in his brain,
and I wanted Mason to be wearing the equipment for 24 hours because the test
would be more sensitive," Saul said. "But the family's insurance
would allow only a spot EEG by an in-network adult neurologist." The
spot EEG was normal.
Yet Mason's symptoms continued to be disturbing, and six months later he
seemed to be deteriorating. Saul ordered an MRI, which confirmed her
suspicions of a serious neurological disorder. "I was paged by a
neuroradiologist who told me it was the most disorganized brain scan they had
ever seen, and it was consistent with leukodystrophy," Saul said.
After confirmation of the diagnosis, Mason was referred to the bone-marrow
transplant program at the University of Minnesota, but by that time it was too
late. "They felt his condition was so advanced that by the time they
would be able to decelerate the process with a bone marrow transplant, he
would have been in a vegetative state," Saul said. "They gave him
six months to live. I saw him once or twice before he died."
Shortly before Mason's death, Kelling began to research Mason's illness and
came upon the Hunter's Hope Foundation, an advocacy organization for universal
"She sent me this pamphlet outlining the discrepancies in newborn
screening from state to state," Saul said. "I didn't know how to
make meaning of it, but I thought the best way to honor her and Mason was to
make other physicians aware of the discrepancies."
Saul brought the cause to the American Academy of Child and Adolescent
Psychiatry—where she is a member of the academy's Assembly of Regional
Organizations—in the form of a resolution for universal neonatal
screening of the 29 "core" genetic illnesses (see
Screening Panel for Newborns)
recommended by the American College of Medical
Genetics (ACMG). Passed unanimously, the resolution also called for the
academy to bring the issue to the attention of the AMA.
Academy assembly members Louis Kraus, M.D., and David Fassler, M.D., then
brought it to the AMA's Section Council on Psychiatry, of which they are also
members. In June the section council brought to the AMA House of Delegates a
resolution calling on the association to "advocate for mandatory,
comprehensive, and uniform screening of newborns for major hereditable
Debate on the resolution was largely favorable, and the House of Delegates
voted to reaffirm a 2006 AMA report on the issue consistent with the
resolution's purpose. "The outcome was a good discussion, which
definitely helped increase awareness of the issues pertaining to newborn
screening," said Fassler.
Even in the short period since Mason's death, the number of states
requiring or recommending the full 29-condition panel of ACMG genetics
tests—or close to the full panel—has increased dramatically.
As it happens, X-linked ADL is not among the 29 conditions. It was only in
2006 that researchers at the Kennedy Krieger Institute published results of a
preliminary test of a newborn screen for the disease. Pilot-testing of the
screen is expected to be completed in two years.
Decisions about neonatal genetic screening raise difficult ethical
questions wrought by the revolution in genetics: What is the availability of
cost-effective treatment for a disorder diagnosed by testing? How does one
weigh the relative merits of screening for a disease such as X-linked ADL for
which there is no cure, but only expensive ameliorative therapies that
may—or may not—lengthen survival? And how does one account for the
possibility that better treatments or cures may become available in the
future, though at the time of testing they may not exist?
At Mason's memorial last year, a hundred or more friends gathered in the
park to celebrate the short life of the child who loved his sister Kayla and
SpongeBob Squarepants. They sang the SpongeBob theme song ("Who
lives in a pineapple under the sea"?) and released 250 helium
balloons—scrawled with messages to Mason using Sharpie
markers—into the sky.
"He was a very colorful little boy," his mother told
Psychiatric News. "He was very much in love with his sister.
Even right up to the end, nobody else could get him to laugh the way Kayla
Information about the Kennedy Krieger Institute is posted at<www.kennedykrieger.org/>.
Information about the Hunter's Hope Foundation is posted at<www.huntershope.org>.
The American College of Medical Genetics' Web site is<www.acmg.net>.▪